Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 32 Requests for Deregulation Received in Pharmaceutical, Healthcare Fields
July 19, 2004
- Korosho to Recommend Measures to Ensure Safe Blood Transfusion
July 19, 2004
- PMDA Receives 1st Application for Priority Consultation Service
July 19, 2004
- REGULATORY NEWS IN BRIEF
July 19, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 19, 2004
- FY2004 Is Critical for Restoring Good Financial Results: Mr Miyatake of Dainippon
July 19, 2004
- Takara Bio Supplies RetroNectin to NCI of the US for Gene Therapy Trial
July 19, 2004
- MEDICAL DEVICE NEWS IN BRIEF
July 19, 2004
- JGA to Hold 1st Scientific Meeting in Jan. 2005
July 19, 2004
- FPMAJ, EPMA Call For Twice-a-year Listing for Generics
July 19, 2004
- Dr Kodama Stresses Advantage of PTX3 as Marker of Arteriosclerosis: CMIC Seminar
July 19, 2004
- BUSINESS NEWS IN BRIEF
July 19, 2004
- Response Rates to Newest Antidepressants Reach 50-70%: JSMD Symposium
July 19, 2004
- WEBSITE NEWS
July 19, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 19, 2004
- Annual Business Results
July 19, 2004
- OTC NEWS IN BRIEF
July 19, 2004
- NEW PRODUCTS
July 19, 2004
- DIAGNOSTIC NEWS IN BRIEF
July 19, 2004
- Levitra Sales See Unexpected Growth: Mr Eiki of Bayer Yakuhin
July 19, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…